Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Oral & Dental

Mechanisms of photobiomodulation therapy in treating and preventing antineoplastic-induced oral mucositis: a systematic review

The findings suggested that the mechanism of action of PBMT in OM involves modulation of the inflammatory response, balancing oxygen reactive species generation, and expression of factors related to healing or repair.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors report a systematic review of seven eligible studies on how photobiomodulation therapy may work for oral mucositis caused by cancer treatment. They describe reduced pro-inflammatory cytokines, increased anti-inflammatory cytokines, and changes in antioxidant and healing-related factors. The authors conclude that further studies are needed to clarify these mechanisms.

Studies included
7
Who or what was studied
Patients with oral mucositis caused by antineoplastic (chemotherapy or radiotherapy) treatment
Limits stated in the abstract
The abstract reports only seven eligible studies and states that further studies are needed to elucidate the mechanisms.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Purpose

To conduct a systematic review of the mechanisms of photobiomodulation therapy (PBMT) for treating or preventing oral mucositis (OM) caused by antineoplastic therapy.

Methods

Following PRISMA 2020 guidelines, a search was conducted in Medline, Latin American and Caribbean Health Sciences Literature (LILACS), Scientific Electronic Library Online (SciELO), and Bibliografia Brasileira de Odontologia from August to September 2023 using descriptors related to OM and laser therapy. Studies on the mechanisms of photobiomodulation in OM were included. Randomized (RCTs) or non-randomized trials from the past 10 years were reviewed. Risk of bias was assessed using RoB 2.0 and ROBINS-I tools.

Results

A total of 355 studies was identified. After the screening, seven met the eligibility criteria. The RCTs showed a low risk of bias. PBMT reduced OM incidence in patients undergoing chemotherapy/radiotherapy. PBMT decreased pro-inflammatory cytokines (interleukin-6, tumor necrosis factor-α) and increased anti-inflammatory cytokines (interleukin-4, interleukin-10). It also modulated inflammatory mediators, enhancing the antioxidant enzyme superoxide dismutase and overexpressing genes for keratinocyte differentiation, aiding injury repair.

Conclusion

The findings suggested that the mechanism of action of PBMT in OM involves modulation of the inflammatory response, balancing oxygen reactive species generation, and expression of factors related to healing or repair. Further studies are needed to elucidate these mechanisms and optimize treatment protocols.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a review: what to check before relying on this kind of research.

Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Systematic review, Oral mucositis, Risk of bias, Laser. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies

Oral & Dental

Photobiomodulation for the treatment and prevention of chemotherapy- and/or radiotherapy-induced oral mucositis in cancer patients: a systematic review and meta-analysis of randomized clinical trials published in the last six years

Evidence from recent randomized clinical trials confirms that PBMT is highly effective for the management of oral mucositis, reducing its incidence and severity, improving quality of life and treatment adherence, and potentially lowering healthcare costs during cancer therapy.

Review · May 7, 2026 · G R et al.